Tariquidar
- Generic Name
- Tariquidar
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C38H38N4O6
- CAS Number
- 206873-63-4
- Unique Ingredient Identifier
- J58862DTVD
- Indication
Investigated for use/treatment in ovarian cancer, lung cancer, and breast cancer.
- Associated Conditions
- -
- Associated Therapies
- -
PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy
- First Posted Date
- 2004-05-06
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00082368
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
Phase 2
Completed
- Conditions
- Lung NeoplasmsOvarian NeoplasmsCervix NeoplasmsRenal Neoplasms
- Interventions
- First Posted Date
- 2003-09-16
- Last Posted Date
- 2012-10-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00069160
- Locations
- 🇺🇸
National Institutes of Health, Bethesda, Maryland, United States
Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Wilms' TumorColdrhood CancerSarcomaAdenaocortical CarcinomaRefractory Cancer
- Interventions
- First Posted Date
- 2001-02-19
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT00011414
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath